+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06541574

Evaluating Methotrexate to Prevent Proliferative Vitreoretinopathy After Primary Retinal Detachment Repair A Phase 2 Randomized, Double-Masked Trial at Cincinnati Eye Institute

Led by Cincinnati Eye Institute, Southwest Ohio · Updated on 2026-10-29

860

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating methotrexate to prevent proliferative vitreoretinopathy PVR after primary surgery for rhegmatogenous retinal detachment. PVR is a complication that can cause retinal detachment to recur and lead to poor visual outcomes. This study is a phase 2, randomized, double-masked clinical trial conducted at the Cincinnati Eye Institute, aiming to find effective strategies to reduce PVR, which currently lacks proven preventive medication. Participants are randomly assigned to one of four groups receiving no methotrexate, receiving methotrexate only by postoperative injections at weeks 1, 3, 6, and 10, receiving methotrexate only by intraoperative infusion during surgery, or receiving both intraoperative infusion and postoperative injections. The intraoperative infusion involves methotrexate mixed into the balanced salt solution used during surgery, and injections are given into the eye. Sham injections are used for masking. The study compares these approaches to assess which may best prevent PVR. Participants will undergo 11 visits over about 12 months, including screening, surgery, and multiple postoperative assessments. Visual acuity, intraocular pressure, eye examinations, presence of PVR or epitheliopathy, and any methotrexate side effects will be monitored. Pregnancy screening and contraception discussions occur when appropriate. Researchers will measure outcomes such as PVR incidence, need for reoperations, visual acuity, and treatment-related complications to evaluate methotrexates role in preventing PVR after retinal detachment surgery.

CONDITIONS

Brief Title

Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

Research Team

C

Christopher Riemann, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here